drugset / Trial / NCT02491606
Evaluation of Weekly Tafenoquine
Phase 2
Completed
249 enrolled
U.S. Army Medical Research and Development Command
SmithKline Beecham · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is a phase 2b, placebo controlled, randomized, blinded study of the efficacy of WR 238605, a new primaquine analog, compared to placebo as chemosuppression of P. falciparum malaria in Nyanza Province, western Kenya.
Timeline
- Start
- 1997-05
- Primary completion
- 1997-09
- Completion
- 1998-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tafenoquine | Small molecule | 200 mg | — |
| Subject | Tafenoquine | Small molecule | 400 mg | — |